Emerging studies reveal advances in RNA therapeutics and protein degraders, with AI-driven methods spotlighting novel targets and improving treatment efficacy. A machine learning approach now enables precise identification of senescent cells via nuclear morphology, supporting aging and disease research. Simultaneously, developments in targeted protein degradation, including PROTAC and molecular glues, expand potential therapies against previously undruggable proteins. Companies such as Kymera Therapeutics and Arvinas continue to validate this modality’s clinical promise in cancer and neurodegeneration applications.